UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 20, 2011
THERAGENICS CORPORATION®
(Exact name of registrant as specified in charter)
Delaware
|
001-14339
|
58-1528626
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
5203 Bristol Industrial Way
Buford, Georgia 30518
(Address of principal executive offices / Zip Code)
(770) 271-0233
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act. |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Set forth below is a brief description of each matter voted upon at Theragenics Corporation’s 2011 annual meeting of stockholders held on May 20, 2011, and the voting results with respect to each matter.
1.
|
A proposal to elect two Class I directors to serve for a term expiring in 2014:
|
Class I Director
|
Votes For
|
Votes
Withheld
|
Broker
Non-votes
|
|||||||
John V. Herndon
|
18,058,180 | 564,397 | 8,044,967 | |||||||
Peter A. A. Saunders
|
17,599,315 | 1,023,262 | 8,044,967 |
2.
|
A proposal to ratify the appointment of Dixon Hughes PLLC as the Company’s independent auditor for the year ending December 31, 2011:
|
For
|
Against
|
Abstentions
|
Broker
Non-votes
|
||||||||
26,405,461 | 135,478 | 127,205 | 0 |
Pursuant to the foregoing votes, Mr. Herndon and Mr. Saunders were elected to serve as Class I directors and Dixon Hughes PLLC was ratified as the Company’s independent auditors for the Company’s fiscal year ending December 31, 2011.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
THERAGENICS CORPORATION | ||||
(Registrant) | ||||
Dated: May 24, 2011
|
|
By:
|
/s/ M. Christine Jacobs | |
M. Christine Jacobs | ||||
Chief Executive Officer | ||||
3